Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CD3+CD56+ Cytokine-Induced Killer Cell (CIK)
- Target
- CIK
- Molecular classification
- Immune cell, Effector cell, T cell subset, Natural killer cell-like
01
Overview
CD3+CD56+ cytokine-induced killer (CIK) cells are a unique population of immune effector cells that exhibit both T cell and natural killer (NK) cell-like properties. They are generated ex vivo by stimulating PBMCs or T-cell subsets with a combination of cytokines, typically IFN-γ, anti-CD3 antibody, and IL-2. They possess potent cytolytic activity against tumor targets and can kill in an MHC-restricted or -unrestricted manner. CIK therapy is being explored for cancer immunotherapy due to their ability to be expanded easily ex vivo and their anti-tumor activity.
- Other names
- Cytokine-induced killer cellCD3+CD56+ CIKCIK cells
02
Mechanism of action
Cytotoxicity against tumor cells via MHC-restricted and MHC-unrestricted mechanisms; cytokine secretion to modulate immune response.
03
Biological functions
CytotoxicityImmune responseTumor cell lysisCytokine production (IFN-γ, TNFα, IL-2, GM-CSF)Viral infection control
04
Disease associations
CancerViral infectionsPost-transplant complications
05
Safety considerations
Cytokine release syndrome (CRS)Graft-versus-host disease (GvHD)
06
Interacting drugs
Interferon-gamma (IFN-γ)
2 more in the full profile.
07
Biomarkers
CD3 expressionCD56 expressionNKG2D expressionDNAM-1 expression
Beyond the preview
Go deeper on CD3+CD56+ Cytokine-Induced Killer Cell (CIK).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD3+CD56+ Cytokine-Induced Killer Cell (CIK).